Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 1.00 |
| ▸ | TK1 | P04183 | 5/20 | 0.53 |
| ▸ | NT5M | Q9NPB1 | 1/20 | 0.48 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1619438 | 1.00 | DHFR (1.00) | DHFRTK1NT5MSTING1ALB | |
| SCHEMBL30968383 | 1.00 | DHFR (1.00) | DHFRTK1NT5MSTING1ALB | |
| SCHEMBL2408425 | 0.86 | DHFR (0.75) | DHFRSTING1 | |
| SCHEMBL29144164 | 0.85 | DHFR (0.73) | DHFRTK1NT5MALBPKM | |
| SCHEMBL10239772 | 0.84 | DHFR (0.72) | DHFRTK1NT5M | |
| SCHEMBL24852241 | 0.81 | DHFR (0.68) | DHFRTK1NT5MALBPKM | |
| SCHEMBL23105032 | 0.81 | DHFR (0.68) | DHFRTK1NT5MALBPKM | |
| SCHEMBL12303789 | 0.81 | DHFR (0.67) | DHFRTK1NT5MALBPKM | |
| SCHEMBL31084252 | 0.81 | DHFR (0.67) | DHFRTK1NT5MALBPKM | |
| SCHEMBL2455603 | 0.81 | DHFR (0.67) | DHFRTK1NT5MALBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11819550-B2 | Liquid protein formulations containing cyclic adenosine monophosphate (cAMP) or adenosine triphosphate (ATP) | EAGLE BIOLOGICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11819550-B2 | Liquid protein formulations containing cyclic adenosine monophosphate (cAMP) or adenosine triphosphate (ATP) | EAGLE BIOLOGICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-10821184-B2 | Liquid protein formulations containing thiamine pyrophosphate (TPP) | EAGLE BIOLOGICS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20180153997-A1 | Liquid Protein Formulations Containing Organophosphates | EAGLE BIOLOGICS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180153997-A1 | Liquid Protein Formulations Containing Organophosphates | EAGLE BIOLOGICS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9913905-B2 | Liquid pharmaceutical formulations for injection comprising thiamine pyrophosphate 1-(3-aminopropyl)-2-methyl-1H-imidazole and uses thereof | EAGLE BIOLOGICS, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-9913905-B2 | Liquid pharmaceutical formulations for injection comprising thiamine pyrophosphate 1-(3-aminopropyl)-2-methyl-1H-imidazole and uses thereof | EAGLE BIOLOGICS, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| WO-2016054259-A1 | POLYSACCHARIDE AND NUCLEIC ACID FORMULATIONS CONTAINING VISCOSITY-LOWERING AGENTS | Arsia Therapeutics, Inc. (US) | 2016-04-07 | — | — | WO | disclosed |
| US-20150071921-A1 | LIQUID PROTEIN FORMULATIONS CONTAINING ORGANOPHOSPHATES | EAGLE BIOLOGICS, INC. | 2015-03-12 | — | — | US | disclosed |
| US-20150071921-A1 | LIQUID PROTEIN FORMULATIONS CONTAINING ORGANOPHOSPHATES | EAGLE BIOLOGICS, INC. | 2015-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819550-B2 | Liquid protein formulations containing cyclic adenosine monophosphate (cAMP) or adenosine triphosphate (ATP) | PDE7A, PDE8A, PDE8B | DHFR 4463/4885TK1 561/4885NT5M 1113/4885 |
| US-10821184-B2 | Liquid protein formulations containing thiamine pyrophosphate (TPP) | PLPBP, ITPA, PLTP | DHFR 548/4885TK1 114/4885NT5M 1261/4885 |
| US-20150071921-A1 | LIQUID PROTEIN FORMULATIONS CONTAINING ORGANOPHOSPHATES | IGFBP1, IGFBP5, IGF2BP1 | DHFR 3700/4885TK1 2774/4885NT5M 3247/4885 |
| US-20180153997-A1 | Liquid Protein Formulations Containing Organophosphates | IGFBP1, IGFBP5, IGF2BP1 | DHFR 3700/4885TK1 2774/4885NT5M 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.